Table 2.
Protein name | Peptides matched/total | Coverage, % | MOWSE score | ||||
---|---|---|---|---|---|---|---|
Control | Insulin | E2 | Glucagon | ||||
MMP-9_HUMAN | MMP-9 | + | 18/85 | 25 | 240 | ||
MMP-8_HUMAN | MMP-8 | 15/85 | 31 | 240 | |||
CATG_HUMAN | Cath. G | 15/77 | 40 | 75 | |||
PERM_HUMAN | + | MPO | 17/85 | 21 | 119 | ||
TRFL_HUMAN | + | LF | + | + | 29/85 | 43 | 240 |
ALBU_HUMAN | + | Albumin | 15/28 | 24 | 130 | ||
NGAL_HUMAN | + | NGAL | + | 7/15 | 42 | 105 | |
LYSC_HUMAN | + | Lysozyme∗ | + | 31 | 98 | ||
S10A9_HUMAN | + | S100-A9 | + | + | 9/19 | 48 | 147 |
S10A8_HUMAN | + | S100-A8 | + | 5/30 | 44 | 84 |
Neutrophils were attached to fibronectin for 20 minutes under control conditions (marked +), or in the presence of 0.1 μM insulin, 0.1 μM E2, or 0.1 μg glucagon. Mass spectrometric analysis data were taken from experiments with insulin. Analogous proteins that were identified in control experiments or in experiments with E2 or glucagon are marked (+). Mass spectrometric data for cathepsin G are taken from experiments with glucagon, and those for albumin and S100A8 from experiments with E2. Proteins were separated by SDS-PAGE and identified by mass spectrometric analysis. ∗Protein was identified by MSMS analysis. Proteins identified in two or three analogous experiments were included in the list.